An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Timo Minssen, Aaron Kesselheim, Jonathan Darrow

A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
OriginalsprogEngelsk
TidsskriftNature Biotechnology
Vol/bind37
Udgave nummer1
Sider (fra-til)21-22
Antal sider2
ISSN1087-0156
DOI
StatusUdgivet - 3 jan. 2019

Links

ID: 204531230